Partnership Further Advances Aggressive Business Development Strategy
Pre-eminent Tissue Culture Company Provides Access to Substantial Network of CPG Companies
3 Rivers’ Technology Transfer Capabilities Expand CTT’s Operational Capacity
HAMILTON, ON, Sept. 8, 2020 /PRNewswire/ – CTT Pharmaceutical Holdings, Inc., (the “Company” or “CTT”) (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, today announced that it has entered into a business development partnership with 3 Rivers Biotech, a pre-eminent tissue culture company. Under the agreement, 3 Rivers will leverage its network of suppliers to and manufacturers of Consumer Packaged Goods (CPG) to secure commercial partnerships based on CTT’s patented sublingual wafer technology.
Additionally, the agreement includes the ability for CTT to utilize 3 Rivers’ operational capabilities to execute technology transfers and project implementation for new customers, providing a cost-efficient and de-risked expansion of CTT’s operational capacity.
3 Rivers’ is one of